P J Mannon

Summary

Affiliation: National Institutes of Health
Country: USA

Publications

  1. ncbi Peptide YY as a growth factor for intestinal epithelium
    Peter J Mannon
    Mucosal Immunity Section, Laboratory of Clinical Investigation, National Institute of Allergy and Infectious Diseases, National Institutes of Health, Bethesda, Maryland 20892, USA
    Peptides 23:383-8. 2002
  2. ncbi Excess IL-12 but not IL-23 accompanies the inflammatory bowel disease associated with common variable immunodeficiency
    Peter J Mannon
    Mucosal Immunity Section, Laboratory of Host Defense, NIAID, NIH, Bethesda, Maryland 20892, USA
    Gastroenterology 131:748-56. 2006
  3. ncbi Peptide YY Y1 receptor activates mitogen-activated protein kinase and proliferation in gut epithelial cells via the epidermal growth factor receptor
    P J Mannon
    Gastroenterology Section, Box 3913, Duke University Medical Center, Durham, NC 27710, USA
    Biochem J 350:655-61. 2000
  4. ncbi Anti-interleukin-12 antibody for active Crohn's disease
    Peter J Mannon
    Mucosal Immunity Section, National Institute of Allergy and Infectious Diseases, National Institutes of Health, Bethesda, MD 20892, USA
    N Engl J Med 351:2069-79. 2004
  5. ncbi The neuropeptide Y/peptide YY Y1 receptor is coupled to MAP kinase via PKC and Ras in CHO cells
    P J Mannon
    Duke University Medical Center, Durham, North Carolina, USA
    Biochem Biophys Res Commun 246:91-4. 1998
  6. ncbi Both IL-12p70 and IL-23 are synthesized during active Crohn's disease and are down-regulated by treatment with anti-IL-12 p40 monoclonal antibody
    Ivan J Fuss
    Mucosal Immunity Section, Laboratory of Host Defenses, National Institute of Allergy and Infectious Diseases, National Institutes of Health, Bethesda, MD 20892, USA
    Inflamm Bowel Dis 12:9-15. 2006
  7. ncbi Persistence of HIV in gut-associated lymphoid tissue despite long-term antiretroviral therapy
    Tae Wook Chun
    National Institute of Allergy and Infectious Diseases, National Institutes of Health, Bethesda, Maryland 20892, USA
    J Infect Dis 197:714-20. 2008
  8. ncbi Peptide YY/neuropeptide Y Y1 receptor expression in the epithelium and mucosal nerves of the human colon
    P J Mannon
    Department of Medicine, Durham Veterans Affairs Medical Center, NC 27710, USA
    Regul Pept 83:11-9. 1999
  9. ncbi Cycling of gut mucosal CD4+ T cells decreases after prolonged anti-retroviral therapy and is associated with plasma LPS levels
    E J Ciccone
    Laboratory of Immunoregulation, National Institute of Allergy and Infectious Diseases, Bethesda, Maryland, USA
    Mucosal Immunol 3:172-81. 2010
  10. ncbi Multiple endoscopic biopsies in research subjects: safety results from a National Institutes of Health series
    Michael D Yao
    National Institute of Diabetes and Digestive and Kidney Diseases, National Institutes of Health, Bethesda, Maryland, USA
    Gastrointest Endosc 69:906-10. 2009

Collaborators

Detail Information

Publications12

  1. ncbi Peptide YY as a growth factor for intestinal epithelium
    Peter J Mannon
    Mucosal Immunity Section, Laboratory of Clinical Investigation, National Institute of Allergy and Infectious Diseases, National Institutes of Health, Bethesda, Maryland 20892, USA
    Peptides 23:383-8. 2002
    ..In addition to proposed physiologic effects on gut mucosal maintenance, PYY proliferative effects may be hypothesized to contribute to pathophysiologic consequences of stimulated growth...
  2. ncbi Excess IL-12 but not IL-23 accompanies the inflammatory bowel disease associated with common variable immunodeficiency
    Peter J Mannon
    Mucosal Immunity Section, Laboratory of Host Defense, NIAID, NIH, Bethesda, Maryland 20892, USA
    Gastroenterology 131:748-56. 2006
    ..This study was designed to assess the status of the gastrointestinal tract and to define the mucosal immune abnormalities in patients with and without symptomatic gut inflammatory disease...
  3. ncbi Peptide YY Y1 receptor activates mitogen-activated protein kinase and proliferation in gut epithelial cells via the epidermal growth factor receptor
    P J Mannon
    Gastroenterology Section, Box 3913, Duke University Medical Center, Durham, NC 27710, USA
    Biochem J 350:655-61. 2000
    ..These results demonstrate a novel pathway involving G(i)/G(o) protein, EGFR and PKC to activate MAPK. Further, they support a role for PYY and the Y1R in regulating growth in human colonic epithelium...
  4. ncbi Anti-interleukin-12 antibody for active Crohn's disease
    Peter J Mannon
    Mucosal Immunity Section, National Institute of Allergy and Infectious Diseases, National Institutes of Health, Bethesda, MD 20892, USA
    N Engl J Med 351:2069-79. 2004
    ..Crohn's disease is associated with excess cytokine activity mediated by type 1 helper T (Th1) cells. Interleukin-12 is a key cytokine that initiates Th1-mediated inflammatory responses...
  5. ncbi The neuropeptide Y/peptide YY Y1 receptor is coupled to MAP kinase via PKC and Ras in CHO cells
    P J Mannon
    Duke University Medical Center, Durham, North Carolina, USA
    Biochem Biophys Res Commun 246:91-4. 1998
    ..These data suggest a novel mechanism for Y1 receptor coupling to MAPK, which is at once pertussis toxin-sensitive as well as PKC- and Ras-dependent...
  6. ncbi Both IL-12p70 and IL-23 are synthesized during active Crohn's disease and are down-regulated by treatment with anti-IL-12 p40 monoclonal antibody
    Ivan J Fuss
    Mucosal Immunity Section, Laboratory of Host Defenses, National Institute of Allergy and Infectious Diseases, National Institutes of Health, Bethesda, MD 20892, USA
    Inflamm Bowel Dis 12:9-15. 2006
    ..These molecules contain an identical p40 chain that is bound to a p35 chain in IL-12 and a p19 chain in IL-23, making both potentially susceptible to modulation by an anti-IL-12p40 monoclonal antibody (mAb)...
  7. ncbi Persistence of HIV in gut-associated lymphoid tissue despite long-term antiretroviral therapy
    Tae Wook Chun
    National Institute of Allergy and Infectious Diseases, National Institutes of Health, Bethesda, Maryland 20892, USA
    J Infect Dis 197:714-20. 2008
    ....
  8. ncbi Peptide YY/neuropeptide Y Y1 receptor expression in the epithelium and mucosal nerves of the human colon
    P J Mannon
    Department of Medicine, Durham Veterans Affairs Medical Center, NC 27710, USA
    Regul Pept 83:11-9. 1999
    ....
  9. ncbi Cycling of gut mucosal CD4+ T cells decreases after prolonged anti-retroviral therapy and is associated with plasma LPS levels
    E J Ciccone
    Laboratory of Immunoregulation, National Institute of Allergy and Infectious Diseases, Bethesda, Maryland, USA
    Mucosal Immunol 3:172-81. 2010
    ..These data suggest that gut T-cell activation and microbial translocation may be interconnected whereas prolonged ART may decrease activation and restore gut CD4+ T cells...
  10. ncbi Multiple endoscopic biopsies in research subjects: safety results from a National Institutes of Health series
    Michael D Yao
    National Institute of Diabetes and Digestive and Kidney Diseases, National Institutes of Health, Bethesda, Maryland, USA
    Gastrointest Endosc 69:906-10. 2009
    ..Routine endoscopic mucosal biopsies are generally considered safe. However, the outcomes of performing large numbers of biopsies in subjects enrolled in research protocols have not been reported...
  11. ncbi Successful granulocyte-colony stimulating factor treatment of Crohn's disease is associated with the appearance of circulating interleukin-10-producing T cells and increased lamina propria plasmacytoid dendritic cells
    P J Mannon
    Mucosal Immunity Section, Laboratory of Host Defense, NIAID, NIH, Bethesda, MD, USA
    Clin Exp Immunol 155:447-56. 2009
    ....
  12. ncbi Anti-IgE treatment of eosinophil-associated gastrointestinal disorders
    Shabnam Foroughi
    Laboratory of Allergic Diseases, National Institute of Allergy and Infectious Diseases, National Institutes of Health, Bethesda, MD, USA
    J Allergy Clin Immunol 120:594-601. 2007
    ..Eosinophil-associated gastrointestinal disorders (EGIDs) are commonly associated with atopy and are being recognized with increasing frequency. Current therapy for EGIDs is inadequate...